Effect of efonidipine, a novel dihydropyridine derivative, on myocardial metabolic changes induced by coronary artery ligation in dogs: Comparison with nifedipine

Fundamental and Clinical Pharmacology

Volumn 11, Issue 3, 1997, Pages 245-251

  Yokoyama, T ^a   Ichihara, K ^a,b   Abiko, Y ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Dog heart; Efonidipine; Ischemia; Metabolism; Nifedipine

Indexed keywords

DIHYDROPYRIDINE DERIVATIVE; EFONIDIPINE; NIFEDIPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CARBOHYDRATE METABOLISM; CHRONOTROPISM; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DOG; FEMALE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; METABOLISM; NONHUMAN; PRIORITY JOURNAL;

EID: 0031001182     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.1997.tb00192.x     Document Type: Article

References (33)

1. Abe Y, Ichihara K, Abiko Y. Effects of MCI-176, a new quinazolinone calcium antagonist, on myocardial energy and carbohydrate metabolism in ischemic dog hearts. Biochem Pharmacol 1991;41:445-51
2. Atkinson DE, Walton GM. Adenosine triphosphate conservation in metabolic regulation. Rat liver citrate cleavage enzyme. J Biol Chem 1967;24:3239-41
3. Bergmeyer HU, ed. Methods of Enzymatic Analysis. New York: Academic Press, 1974;1238-42 (G6P, F6P), 1314-9 (FDP), 1464-8 (lactate), 1777-81 (CrP), 2101-10 (ATP), 2127-31 (ADP, AMP)
4. Bush LR, Romson J, Ash JL, Lucchesi BR. Effects of diltiazem on the extent of ultimate myocardial injury resulting from temporary coronary artery occlusion in dogs. J Cardiovasc Pharmacol 1982;4:285-96
5. Davenport N, Goldstein RE, Bolli R, Epstein SE. Blood flow to infarct and serving myocardium: implications regarding the action of verapamil on the acutely ischemic dog heart. J Am Coll Cardiol 1984;3:956-65
6. Gebert G, Benzing H, Strohm M. Changes in the interstitial pH of dog myocardium in response to local ischemia, hypoxia, hyper- and hypocapnia, measured continuously by means of glass microelectrodes. Pflügers Arch 1971;329: 72-81
7. Henry PD, Schuchleib R, Borda LJ, Roberts R, Williamson JR, Sobel BE. Effects of nifedipine on myocardial perfusion and ischemic injury in dogs. Circ Res 1987;43:372-80
8. Ichihara K, Abiko Y. Difference between endocardial and epicardial utilization of glycogen in the ischemic heart. Am J Physiol 1975;229:1585-9
9. Ichihara K, Abiko Y. Effect of nadolol, a β-adrenoceptor blocking agent, on myocardial metabolism in the dog ischaemic heart. J Pharm Pharmacol 1987;39:604-8
10. Ichihara K, Haga N, Abiko Y. Is ischemia-induced pH decrease of dog myocardium respiratory or metabolic acidosis? Am J Physiol 1984;246:H652-7
11. Ichihara K, Ichihara M, Abiko Y. Involvement of beta adrenergic receptors in decrease of myocardial pH during ischemia. J Pharmacol Exp Ther 1979a;209:275-81
12. Ichihara K, Ichihara M, Abiko Y. Effect of verapamil and nifedipine on ischemic myocardial metabolism in dogs. Arzneim Forsch 1979b;29:1539-44
13. Ichihara K, Ichihara M, Abiko Y. Effect of niludipine on ischemic myocardial metabolism in the dog. Arzneim Forsch 1980;30:785-91
14. Ichihara K, Maie S, Abiko Y. Effect of flunarizine on ischemic myocardial metabolism in dogs. Eur J Pharmacol 1989; 165:19-27
15. Jennings RB, Steenbergen C. Nucleotide metabolism and cellular damage in myocardial ischemia. Annu Rev Physiol 1985;47:727-49
16. Kern MJ. Perspective: The cellular influences of calcium antagonists on systemic and coronary hemodynamics. Am J Cardiol 1992;69:3-7B
17. Majid PA, Jong JD. Acute hemodynamic effects of nifedipine in patients with ischemic heart disease. Circulation 1982;65:1114-8
18. Masuda Y, Iwata T, Yamashita T, Sakai T, Hibi M, Tanaka S, Shigenobu K, Kasuya Y. Vasorelaxing and receptor binding properties of NZ-105, a novel dihydropyridine derivative, in isolated rabbit aorta. Arch Int Pharmacodyn Ther 1991; 312:86-103
19. Masuda Y, Miyajima M, Shudo C, Tanaka S, Shigenobu K, Kasuya Y. Cardiovascular selectivity of 1,4-dihydropyridine derivative, efonidipine (NZ-105), nicardipine and structure related compounds in isolated guinea-pig tissues. Gen Pharmacol 1995;26:339-45
20. Masuda Y, Takeguchi M, Arakawa C, Sakai T, Hibi M, Tanaka S, Shigenobu K, Kasuya Y. Antihypertensive and diuretic effects of NZ-105, a novel dihydropyridine derivative. Arch Int Pharmacodyn Ther 1990;304:247-64
21. Masuda Y, Tanaka S. Efonidipine hydrochloride: a new calcium antagonist. Cardiovasc Drug Rev 1994;12:123-35
22. Sakai T, Kawamura N, Masuda Y, Hibi M, Tanaka S. Hemodynamic effects of the new dihydropyridine derivative, (±)-2-[benzyl(phenyl)amino]ethyl 1,4-dihydro-2, 6-dimethyl-5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-4-(3-ni trophenyl)-3-pyridinecarboxylate hydrochloride ethanol (NZ-105) in anesthetized dogs. Ôyô Yakuri/Pharmacometrics 1991a;42:43-54
23. Sakai T, Kawamura N, Masuda Y, Oda T, Asada M, Tanaka S, Kato H. Antihypertensive effects of (±)-2-[benzyl(phenyl)amino]ethyl1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl- 2-oxo-1,3,2-dioxaphosphorinan-2-yl)-4-(3-nitrophenyl)-3-pyridinecarboxylate hydrochloride ethanol (NZ-105) in conscious renal hypertensive dogs. Ôyô Yakuri/Pharmacometrics 1991b;42:55-60
24. Shudo C, Masuda Y, Sakai T, Tanaka S, Shigenobu K, Kasuya Y. Studies on the hypotensive mechanisms of NZ-105, a new dihydropyridine derivative, in rats and rabbits. Gen Pharmacol 1993;24;411-8
25. Stone PH, Antman EM, Muller JE, Braunwald E. Calcium channel blocking agents in the treatment of cardiovascular disorders. II. Hemodynamic effects and clinical applications. Ann Int Med 1980;93:886-904
26. Szekeres EU, Vegh A. Importance of myocardial blood flow changes in the protective action of diltiazem in a new model of myocardial ischaemia. Br J Pharmacol 1985;86:341-50
27. Taira N. Difference in cardiovascular profile among calcium antagonist. Am J Cardiol 1987;59:24-9B
28. Tanaka H, Masumiya H, Sekine T, Sijuku T, Sugawara M, Taniguchi H, Terada M, Saito W, Shigenobu K. Myocardial and vascular effects of efonidipine in vitro as compared with nifedipine, verapamil and diltiazem. Gen Pharmacol 1996;27:451-4
29. Trivedi B, Danforth W. Effect of pH on the kinetics of frog muscle phosphofructokinase. J Biol Chem 1966;241: 4110-2
30. Ui M. A role of phosphofructokinase in pH-dependent regulation of glycolysis. Biochem Biophys Acta 1966;124:310-22
31. Vary TC, Reibel DK, Neely JR. Control of energy metabolism of heart muscle. Annu Rev Physiol 1981;43:419-30
32. Watts JA, Maiorano LJ, Mariorano PC. Comparison of the protective effects of verapamil, diltiazem, nifedipine, and buffer containing low calcium upon global myocardial ischemia. J Mol Cell Cardiol 1986;18:255-63
33. Yamashita Y, Masuda Y, Sakai T, Tanaka S, Kasuya Y. NZ-105, a new 1,4-dihydropyridine derivative: Correlation between dihydropyridine receptor binding and inhibition of calcium uptake in rabbit aorta. Jap J Pharmacol 1991; 57:337-48